Immune checkpoint inhibitors (ICIs) targeting PD-1/PD-L1 alone have produced a demonstrable therapeutic benefit in several tumor types; however, their efficacy in gliomas has not been satisfactory (2, 3). This evidence concerns the gene CD274 and neoplasm.